Table 1.
Clinical characteristics of 89 NSCLC patients who were followed up
| All cases | ≤9.43 % | >9.43 % | |||
|---|---|---|---|---|---|
| Disease progression | Censored data | Disease progression | Censored data | ||
| Case | 89 | 28 | 17 | 32 | 12 |
| Gender (male/female) | 51/38 | 17/11 | 9/8 | 17/15 | 8/4 |
| Age (years) | 46.78 ± 9.60 | 52.5 ± 9.43 | 51.29 ± 10.74 | 51.53 ± 8.81 | 59.67 ± 8.67 |
| Histological type | |||||
| Adenocarcinoma | 57 | 19 | 14 | 17 | 7 |
| Squamous cell carcinoma | 21 | 6 | 1 | 9 | 5 |
| Other non-small cell carcinoma | 11 | 3 | 2 | 6 | 0 |
| AJCC stage | |||||
| III (unresectable) | 23 | 11 | 5 | 6 | 1 |
| IV (M1a) | 23 | 8 | 7 | 5 | 3 |
| IV (M1b) | 43 | 9 | 5 | 21 | 8 |
| 1st line chemotherapy | |||||
| Docetaxel + cisplatin | 31 | 8 | 7 | 14 | 2 |
| Pemetrexed + cisplatin | 42 | 14 | 10 | 11 | 7 |
| Gemcitabine + cisplatin | 16 | 6 | 0 | 7 | 3 |